SCHEMBL68609

SCHEMBL68609

C#CCNC(=O)C(F)(F)F

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.50
ALDH1A1 P00352 1/20 0.50
POLB P06746 1/20 0.50
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
EPHX1 P07099 1/20 0.45
CA2 P00918 3/20 0.43
CA14 Q9ULX7 3/20 0.43
CA3 P07451 2/20 0.43
CA5A P35218 2/20 0.43
CA5B Q9Y2D0 2/20 0.43
CA12 O43570 2/20 0.43
CA9 Q16790 2/20 0.43
CA4 P22748 1/20 0.43
CA6 P23280 1/20 0.43
CA7 P43166 1/20 0.43
CA1 P00915 1/20 0.34
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
MAOB P27338 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19630458 0.82 SMN1; SMN2 (0.36) SMN1; SMN2ALDH1A1POLBMEN1KMT2A
SCHEMBL1905868 0.78 ALDH1A1 (0.52) SMN1; SMN2ALDH1A1POLBMEN1KMT2A
SCHEMBL3967600 0.78 CA1 (0.38) SMN1; SMN2POLBCA2CA14CA12
SCHEMBL4742935 0.77 CA2 (0.37) SMN1; SMN2ALDH1A1POLBMEN1KMT2A
SCHEMBL13787269 0.77 ALDH1A1 (0.58) SMN1; SMN2ALDH1A1POLBMEN1KMT2A
SCHEMBL2001127 0.77 MEN1 (0.59) SMN1; SMN2ALDH1A1POLBMEN1KMT2A
SCHEMBL13561305 0.76 CA12 (0.34) SMN1; SMN2ALDH1A1CA2CA14CA12
SCHEMBL3884426 0.76 ALDH1A1 (0.50) SMN1; SMN2ALDH1A1POLBMEN1KMT2A
Trifluoroacetic Acid SCHEMBL28342065 0.76 KDM4E (0.33) SMN1; SMN2ALDH1A1POLBMEN1KMT2A
SCHEMBL16307350 0.74 ALDH1A1 (0.48) SMN1; SMN2ALDH1A1POLBMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 780 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115260262-B Cytosine azide Process for the preparation of compounds 深圳赛陆医疗科技有限公司 2024-09-27 CN claimed
CN-118084996-A Reversible termination nucleotide and application thereof in DNA synthesis sequencing and single molecule sequencing 上海交通大学 2024-05-28 CN claimed
US-11001886-B2 3′-OH unblocked, fast photocleavable terminating nucleotides and methods for nucleic acid sequencing AGILENT TECHNOLOGIES, INC. (US) 2021-05-11 US claimed
US-20190127790-A1 3'-OH UNBLOCKED, FAST PHOTOCLEAVABLE TERMINATING NUCLEOTIDES AND METHODS FOR NUCLEIC ACID SEQUENCING AGILENT TECHNOLOGIES, INC. 2019-05-02 US claimed
CN-103804447-B Aza guanosine and synthetic method thereof and the purposes in DNA sequencing 上海交通大学 2016-08-17 CN claimed
CN-103601779-B The synthetic method of 7-denitrification-2 '-deoxidation-7-halogen 9 substituted guanine nucleosides SHANGHAI JIAO TONG UNIVERSITY (CN) 2016-05-04 CN claimed
CN-103819523-A Method for synthesizing 7-denitrification-7-halogen guanosine UNIV SHANGHAI JIAOTONG 2014-05-28 CN claimed
CN-103804447-A Hybrid azaguanosine as well as synthesis method and application thereof in DNA sequencing UNIV SHANGHAI JIAOTONG 2014-05-21 CN claimed
CN-103601778-A Synthetic method of 7-denitrified-7-substituted guanosine UNIV SHANGHAI JIAOTONG 2014-02-26 CN claimed
CN-103601779-A Synthetic method of 7-denitrified-2'-deoxidized-7-halogen substituted guanosine UNIV SHANGHAI JIAOTONG 2014-02-26 CN claimed
US-8536323-B2 Modified nucleotides PIERCE BIOTECHNOLOGY, INC. (US) 2013-09-17 US claimed
US-20110262917-A1 MODIFIED NUCLEOTIDES PIERCE BIOTECHNOLOGY, INC. (US) 2011-10-27 US claimed
EP-0251786-B1 Alkynylamino-nucleotides DU PONT (US) 1994-11-30 EP claimed
US-5047519-A Alkynylamino-nucleotides E. I. DU PONT DE NEMOURS AND COMPANY (US) 1991-09-10 US claimed
EP-0251786-A2 Alkynylamino-nucleotides E.I. DU PONT DE NEMOURS AND COMPANY (US) 1988-01-07 EP claimed
JP-7316174-A None JP disclosed
JP-5148225-A None JP disclosed
EP-0309969-A2 Method of gene mapping E.I. DU PONT DE NEMOURS AND COMPANY (US) 1989-04-05 EP disclosed
EP-0252683-A2 Process and reagents for DNA sequence analysis E.I. DU PONT DE NEMOURS AND COMPANY (US) 1988-01-13 EP disclosed
EP-0251786-A2 Alkynylamino-nucleotides E.I. DU PONT DE NEMOURS AND COMPANY (US) 1988-01-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190127790-A1 3'-OH UNBLOCKED, FAST PHOTOCLEAVABLE TERMINATING NUCLEOTIDES AND METHODS FOR NUCLEIC ACID SEQUENCING RNGTT, NT5C3B, NSUN2 SMN1; SMN2 3089/4885ALDH1A1 2244/4885POLB 5/4885
US-11001886-B2 3′-OH unblocked, fast photocleavable terminating nucleotides and methods for nucleic acid sequencing RNGTT, NT5C3B, NSUN2 SMN1; SMN2 3118/4885ALDH1A1 2163/4885POLB 5/4885
US-20110262917-A1 MODIFIED NUCLEOTIDES NUDT1, RNMT, RNGTT SMN1; SMN2 3322/4885ALDH1A1 2422/4885POLB 49/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.